Combination Strategies with HSP90 Inhibitors in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Heat shock protein 90 (HSP90) is crucial for cancer cell survival and proliferation by stabilizing oncoproteins.
• HSP90 inhibitors have shown limited success as monotherapies due to toxicity and resistance.

Purpose of the Study:

• To review the mechanistic rationale, evidence, and challenges of HSP90 inhibitor-based combination therapies in oncology.
• To explore future directions for optimizing these combination strategies.

Main Methods:

• Comprehensive literature review of preclinical and clinical studies.
• Analysis of synergistic effects and resistance mechanisms.
• Discussion of emerging technologies for personalized medicine.

Main Results:

• Combination therapies involving HSP90 inhibitors enhance anticancer activity by degrading client proteins and modulating the tumor microenvironment.
• Synergistic effects can overcome resistance mechanisms and boost antitumor immunity.
• Successful implementation requires optimization of dosage, schedules, toxicity management, and patient selection.

Conclusions:

• HSP90 inhibitor-based combination therapies offer enhanced anticancer potential.
• Careful optimization and biomarker-driven patient selection are critical for clinical success.
• Emerging technologies may enable personalized and effective combination regimens.